EUVIMEDEUVIMED entdecken
Crossref

Tumor Lysis Syndrome Associated with Monoclonal Antibodies in Patients with Multiple Myeloma: A Pharmacovigilance Study Based on the FAERS Database

Shuang Xia, Hui Gong, Yichang Zhao, Lin Guo, Yikun Wang, Rui Ma, Bikui Zhang, Mayur Sarangdhar iD, Yoshihiro Noguchi iD, Miao Yan iD

Clinical Pharmacology & Therapeutics · 2023-07 · 114 (1) · 211-219

DOI: 10.1002/cpt.2920 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 11.05.2023. Verfasst von Shuang Xia und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Tumor Lysis Syndrome, Antineoplastic Agents. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although some tumor lysis syndrome (TLS) cases have been reported with patients with multiple myeloma (MM) taking monoclonal antibodies (mAbs), the association between TLS and mAbs remains mostly unknown. We aim to investigate the association between TLS and mAbs and describe clinical features. We conducted a disproportionality analysis to investigate the link between mAbs and TLS by excluding known confounders and compared with other anticancer drugs. The association between mAbs and TLS was evaluated using information component (IC). Drug–drug interaction signals were calculated based on the Ω shrinkage measure. Parametric distribution with the goodness‐of‐fit test was used for the reported time‐to‐onset analysis. From 2016 Q1, to 2022 Q4, a total of 274 TLS with mAbs were reported in the US Food and Drug Administration Adverse Event Reporting System (FAERS) database. There were 27% of patients with TLS with mAbs who died and 20.1% occurred a life‐threatening situation. Daratumumab, elotuzumab, and belantamab mafodotin presented a robust disproportionate signal of TLS after excluding known confounders (IC 025 > 0). Daratumumab had the highest disproportionate signal of TLS among all anticancer drugs for MM. Reported time‐to‐onset analysis showed the median days for TLS with daratumumab, isatuximab, elotuzumab, and belantamab mafodotin were 1.5, 14.5, 5.5, and 5.5 days, respectively. The drug–drug interaction analysis showed the co‐administration of drugs known to increase urate, induce hyperkalemia, or hypocalcemia elevated the reporting frequency for TLS with mAbs (Ω 025 > 0). Our postmarketing pharmacovigilance analysis detected the reporting association of TLS and mAbs in patients with MM. Additional studies with robust epidemiological study designs that can validate these findings are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaTumor Lysis SyndromeAntineoplastic AgentsUnited StatesHumansPharmacovigilanceUnited States Food and Drug AdministrationAntibodies, Monoclonal

Substanzen

Antibodies, MonoclonalAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
  • International Research Center for Precision Medicine, Transformative Technology and Software Services, Changsha, China.
  • Toxicology Counseling Center of Hunan Province, Changsha, China.
  • Division of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Division of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

ORCID-Profile: Mayur Sarangdhar, Yoshihiro Noguchi, Miao Yan

Zitieren

APA

Xia, S., Gong, H., Zhao, Y., Guo, L., Wang, Y., Ma, R., Zhang, B., Sarangdhar, M., Noguchi, Y., & Yan, M. (2023). Tumor Lysis Syndrome Associated with Monoclonal Antibodies in Patients with Multiple Myeloma: A Pharmacovigilance Study Based on the FAERS Database. Clinical Pharmacology & Therapeutics, 114(1), 211-219. https://doi.org/10.1002/cpt.2920

Vancouver

Xia S, Gong H, Zhao Y, Guo L, Wang Y, Ma R, et al. Tumor Lysis Syndrome Associated with Monoclonal Antibodies in Patients with Multiple Myeloma: A Pharmacovigilance Study Based on the FAERS Database. Clinical Pharmacology & Therapeutics. 2023;114(1):211-219. doi:10.1002/cpt.2920

BibTeX
@article{Xia2023,
  author = {Xia, Shuang and Gong, Hui and Zhao, Yichang and Guo, Lin and Wang, Yikun and Ma, Rui and Zhang, Bikui and Sarangdhar, Mayur and Noguchi, Yoshihiro and Yan, Miao},
  title = {Tumor Lysis Syndrome Associated with Monoclonal Antibodies in Patients with Multiple Myeloma: A Pharmacovigilance Study Based on the FAERS Database},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2023},
  volume = {114},
  number = {1},
  pages = {211--219},
  doi = {10.1002/cpt.2920}
}
Kostenlos starten →